Blog | Allogenica

1-year milestones reached for R&D collaborative project with CRCL

We are pleased to announce that the R&D collaborative projet between Allogenica and its academic partner Dr Julien MARIE’s team, based in...

Advanced Therapies' congress 2024

Allogenica was representerd in London 19-20 March, 2024 for the Advanced Therapies congress.

iVenture/Tech&Fest 2024

Allogenica was represented in Grenoble for iVenture and Tech&Fest on February 1-2, 2024. Dr Inna Menkova, CEO, presented the company to...

New facilities for Allogenica at Bioparc Rockefeller in Adenine Building

This is a significant milestone in Allogenica's journey, characterized by enlarged Laboratory space, specially designed to host our...

Allogenica awarded with the Innovation trophy from VCLS Innovation Center

Allogenica's heart and soul is innovation. The innovation that we wish to bring to patients by developing allogeneic CAR-T immediately...

Clara “proof of concept” winner

We are honored to be Clara “proof of concept” recipient. This project arose from interactions between Dr. Inna MENKOVA and Dr. Julien...

Inna MENKOVA awarded the "Femme de la Tech" prize

Inna MENKOVA, CEO of Allogenica, was yesterday awarded the "Femme de la Tech" prize at the 20th edition of the "Décideures" competition...

Allogenica, winner of the 2023 Hello Tomorrow Global Challenge

Inna MENKOVA, CEO of Allogenica, was honored to receive the « Medical biotech & pharmaceuticals » award and to be in the top 3 finalists...

Allogenica, winner of the national i-Lab 2022 competition

Yesterday, Allogenica's co-founders Inna MENKOVA and Jean-Guillaume Lafay went to Cité des sciences et de l'industrie to receive and...

The biotech company Allogenica has secured €500,000 investment from renowned investors to advance innovative biotherapies for cancers.

Founded in January 2022, Allogenica is dedicated to developing universal CAR-T cell-therapies to treat cancers, particularly blood...

The start-up Allogenica is developing innovative biotherapies for blood cancers.

Founded in January 2022, Allogenica specialized in the development of universal Chimeric Antigen Receptor T-cell-therapies (CAR-T...